Renibus Therapeutics is a clinical-stage biotech company that focuses on preventing and treating kidney disease.
Renibus Therapeutics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in September 2023.
Renibus Therapeutics's investors include Oxford Finance LLC.
Renibus Therapeutics is headquartered in Southlake, United States.
Renibus Therapeutics is a clinical-stage biotech company that focuses on preventing and treating kidney disease.
Renibus Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Renibus Therapeutics — Funding & Investors." VCBacked, September 12, 2023, https://www.vcbacked.co/company/renibus-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Renibus Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/renibus-therapeutics
{{cite web |title=Renibus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/renibus-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated